AbbVie ABBV Long-Term Debt
Discontinued — last reported Q4 '25
Long-Term Debt at other companies
Other financials
Where this comes from
Reported directly by AbbVie in its filing.
Tagged under the XBRL concept us-gaap:LongTermDebtAndCapitalLeaseObligations.
The official record: AbbVie’s 10-K, filed February 20, 2026, on SEC EDGAR. View the filing →
Ask your AI about AbbVie's long-term debt.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is AbbVie's long-term debt?
- AbbVie (ABBV) reported long-term debt of $58.94B in Q4 2025.
- How has AbbVie's long-term debt changed year-over-year?
- AbbVie's long-term debt decreased by 2.3% year-over-year, from $60.34B to $58.94B.
- What is the long-term trend for AbbVie's long-term debt?
- Over 5 years (2020 to 2025), AbbVie's long-term debt has grown at a -5.3% compound annual growth rate (CAGR), from $77.55B to $58.94B.
- What does long-term debt mean?
- The total amount of debt that is not due for repayment within the next twelve months.
- How do you interpret long-term debt?
- An increase often signals major acquisition activity or capital investment, while a decrease indicates debt repayment and deleveraging efforts.
- How does long-term debt compare across companies?
- Standard across the pharmaceutical industry, where companies often carry significant debt to finance large acquisitions; peers are compared based on debt-to-EBITDA ratios.